LogicBio Therapeutics (NASDAQ:LOGC) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.
Other equities analysts have also recently issued reports about the company. Barclays assumed coverage on LogicBio Therapeutics in a report on Tuesday, November 13th. They set an “overweight” rating and a $24.00 target price for the company. William Blair assumed coverage on LogicBio Therapeutics in a report on Tuesday, November 13th. They set an “outperform” rating and a $26.00 target price for the company. Finally, Chardan Capital assumed coverage on LogicBio Therapeutics in a report on Tuesday, November 13th. They set a “buy” rating and a $20.00 target price for the company.
LogicBio Therapeutics stock traded down $2.03 during midday trading on Monday, reaching $15.95. 95,200 shares of the stock traded hands, compared to its average volume of 64,432. LogicBio Therapeutics has a 12-month low of $7.26 and a 12-month high of $18.00.
In other news, Director Daniel P. O’connell bought 700,000 shares of the stock in a transaction that occurred on Tuesday, October 23rd. The stock was bought at an average cost of $10.00 per share, for a total transaction of $7,000,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Further Reading: How to Track your Portfolio in Google Finance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.